Progress in Preclinical Research on Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Bronchopulmonary Dysplasia

Shimeng Zhao; Shuang Han

doi:10.1055/a-2704-7823

American Journal of Perinatology, Table of Contents

Am J Perinatol
DOI: 10.1055/a-2704-7823

Review Article

Progress in Preclinical Research on Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Bronchopulmonary Dysplasia

Authors

Shimeng Zhao

¹Department of Neonatology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, P. R. China

²Department of Neonatology, The Fifth Affiliated Hospital of Zunyi Medical University, Zhuhai, Guangzhou, P. R. China
Shuang Han

¹Department of Neonatology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, P. R. China

Abstract

Bronchopulmonary dysplasia (BPD) is the most common chronic respiratory disease in premature infants and affects their survival rate and quality of life. There are no reliable interventions for the prevention or treatment of BPD, but the emergence of mesenchymal stem cell (MSC) therapies has brought new hope. Research has shown that paracrine may be the therapeutic mechanism of action underlying physiological improvements in the lungs of BPD patients treated with MSC therapy. The therapeutic vector in the MSC secretome comprises exosomes with low immunogenicity and stability, and that can easily cross the blood-brain barrier. In the future, exosomes may become the preferred treatment for BPD in clinical settings. Here, we review the progress of preclinical research on the use of MSC-derived exosomes as a promising treatment option for BPD.

Key Points

There is a lack of effective treatment for BPD.
MSCs' therapeutic effect is exerted through paracrine.
MSC-derived exosomes (MSC-Exos) possess similar biological functions to MSCs.
MSC-Exos can repair lung injury in BPD animal models.

Keywords

mesenchymal stem cell - exosomes - therapy - bronchopulmonary dysplasia

Full Text

References

References
1 Bonadies L, Zaramella P, Porzionato A, Perilongo G, Muraca M, Baraldi E. Present and future of bronchopulmonary dysplasia. J Clin Med 2020; 9 (05) 1539
2 Collaco JM, McGrath-Morrow SA. Respiratory phenotypes for preterm infants, children, and adults: bronchopulmonary dysplasia and more. Ann Am Thorac Soc 2018; 15 (05) 530-538
3 Bui DS, Lodge CJ, Burgess JA. et al. Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life. Lancet Respir Med 2018; 6 (07) 535-544
4 Bauer SE, Schneider L, Lynch SK, Malleske DT, Shepherd EG, Nelin LD. Factors associated with neuro developmental impairment in bronchopulmonary dysplasia. J Pediatr 2020; 218: 22-27.e2
5 Yeh TF, Lin YJ, Lin HC. et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004; 350 (13) 1304-1313
6 Chou HC, Li YT, Chen CM. Human mesenchymal stem cells attenuate experimental bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. Am J Transl Res 2016; 8 (02) 342-353
7 You J, Zhou O, Liu J. et al. Human umbilical cord mesenchymal stem cell-derived small extracellular vesicles alleviate lung injury in rat model of bronchopulmonary dysplasia by affecting cell survival and angiogenesis. Stem Cells Dev 2020; 29 (23) 1520-1532
8 Reiter J, Drummond S, Sammour I. et al. Stromal derived factor-1 mediates the lung regenerative effects of mesenchymal stem cells in a rodent model of bronchopulmonary dysplasia. Respir Res 2017; 18 (01) 137
9 Chang YS, Ahn SY, Yoo HS. et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr 2014; 164 (05) 966-972.e6
10 Xia Y, Lang T, Niu Y. et al. Phase I trial of human umbilical cord-derived mesenchymal stem cells for treatment of severe bronchopulmonary dysplasia. Genes Dis 2022; 10 (02) 521-530
11 Wu X, Xia Y, Zhou O. et al. Allogeneic human umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia in children: study protocol for a randomized controlled trial (MSC-BPD trial). Trials 2020; 21 (01) 125
12 Powell SB, Silvestri JM. Safety of intratracheal administration of human umbilical cord blood derived mesenchymal stromal cells in extremely low birth weight preterm infants. J Pediatr 2019; 210: 209-213.e2
13 Lee JW, Fang X, Krasnodembskaya A, Howard JP, Matthay MA. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells 2011; 29 (06) 913-919
14 Liang OD, Mitsialis SA, Chang MS. et al. Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells 2011; 29 (01) 99-107
15 Lee C, Mitsialis SA, Aslam M. et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 2012; 126 (22) 2601-2611
16 Sdrimas K, Kourembanas S. MSC microvesicles for the treatment of lung disease: a new paradigm for cell-free therapy. Antioxid Redox Signal 2014; 21 (13) 1905-1915
17 van der Pol E, Böing AN, Gool EL, Nieuwland R. Recent developments in the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles. J Thromb Haemost 2016; 14 (01) 48-56
18 Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol 2019; 21 (01) 9-17
19 Laffey JG, Matthay MA. Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value. Am J Respir Crit Care Med 2017; 196 (03) 266-273
20 Omar SA, Abdul-Hafez A, Ibrahim S. et al. Stem-Cell therapy for bronchopulmonary dysplasia (BPD) in newborns. Cells 2022; 11 (08) 1275
21 Pierro M, Ionescu L, Montemurro T. et al. Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax 2013; 68 (05) 475-484
22 Harrell CR, Fellabaum C, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome. Cells 2019; 8 (05) 467
23 Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells 2017; 35 (04) 851-858
24 Ferguson SW, Wang J, Lee CJ. et al. The microRNA regulatory landscape of MSC-derived exosomes: a systems view. Sci Rep 2018; 8 (01) 1419
25 Jung JW, Kwon M, Choi JC. et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J 2013; 54 (05) 1293-1296
26 Elahi FM, Farwell DG, Nolta JA, Anderson JD. Preclinical translation of exosomes derived from mesenchymal stem/stromal cells. Stem Cells 2020; 38 (01) 15-21
27 Yin K, Wang S, Zhao RC. Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm. Biomark Res 2019; 7: 8
28 García-Manrique P, Gutiérrez G, Blanco-López MC. Fully artificial exosomes: towards new theranostic biomaterials. Trends Biotechnol 2018; 36 (01) 10-14
29 Charoenviriyakul C, Takahashi Y, Nishikawa M, Takakura Y. Preservation of exosomes at room temperature using lyophilization. Int J Pharm 2018; 553 (1–2): 1-7
30 Chaubey S, Thueson S, Ponnalagu D. et al. Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6. Stem Cell Res Ther 2018; 9 (01) 173
31 Willis GR, Fernandez-Gonzalez A, Anastas J. et al. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med 2018; 197 (01) 104-116
32 Qu M, Lin Q, Huang L. et al. Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson's disease. J Control Release 2018; 287: 156-166
33 Speer CP. Pulmonary inflammation and bronchopulmonary dysplasia. J Perinatol 2006; 26 (Suppl. 01) S57-S62 , discussion S63–S64
34 Ambalavanan N, Carlo WA, D'Angio CT. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics 2009; 123 (04) 1132-1141
35 Viscardi RM. Perinatal inflammation and lung injury. Semin Fetal Neonatal Med 2012; 17 (01) 30-35
36 Pugliese SC, Kumar S, Janssen WJ. et al. A time- and compartment-specific activation of lung macrophages in hypoxic pulmonary hypertension. J Immunol 2017; 198 (12) 4802-4812
37 Mitsi E, Kamng'ona R, Rylance J. et al. Human alveolar macrophages predominately express combined classical M1 and M2 surface markers in steady state. Respir Res 2018; 19 (01) 66
38 Zaramella P, Munari F, Stocchero M. et al. Innate immunity ascertained from blood and tracheal aspirates of preterm newborn provides new clues for assessing bronchopulmonary dysplasia. PLoS One 2019; 14 (09) e0221206
39 Xu N, Shao Y, Ye K. et al. Mesenchymal stem cell-derived exosomes attenuate phosgene-induced acute lung injury in rats. Inhal Toxicol 2019; 31 (02) 52-60
40 Liu JS, Du J, Cheng X, Zhang XZ, Li Y, Chen XL. Exosomal miR-451 from human umbilical cord mesenchymal stem cells attenuates burn-induced acute lung injury. J Chin Med Assoc 2019; 82 (12) 895-901
41 Lee TH, Lee GW, Ziff EB, Vilcek J. Isolation and characterization of eight tumor necrosis factor-induced gene sequences from human fibroblasts. Mol Cell Biol 1990; 10 (05) 1982-1988
42 Zhang C, Zhang B, Wang H, Tao Q, Ge S, Zhai Z. Tumor necrosis factor alpha-stimulated gene-6 (TSG-6) inhibits the inflammatory response by inhibiting the activation of P38 and JNK signaling pathway and decreases the restenosis of vein grafts in rats. Heart Vessels 2017; 32 (12) 1536-1545
43 Mittal M, Tiruppathi C, Nepal S. et al. TNFα-stimulated gene-6 (TSG6) activates macrophage phenotype transition to prevent inflammatory lung injury. Proc Natl Acad Sci U S A 2016; 113 (50) E8151-E8158
44 Wang J, Dong W. Oxidative stress and bronchopulmonary dysplasia. Gene 2018; 678: 177-183
45 Speer CP. Inflammation and bronchopulmonary dysplasia. Semin Neonatol 2003; 8 (01) 29-38
46 Perrone S, Bracciali C, Di Virgilio N, Buonocore G. Oxygen use in neonatal care: a two-edged sword. Front Pediatr 2017; 4: 143
47 Falsaperla R, Lombardo F, Filosco F. et al. Oxidative stress in preterm infants: overview of current evidence and future prospects. Pharmaceuticals (Basel) 2020; 13 (07) 145
48 Saugstad OD. Bronchopulmonary dysplasia-oxidative stress and antioxidants. Semin Neonatol 2003; 8 (01) 39-49
49 Wu Y, Zhang Z, Li J. et al. Mechanism of adipose-derived mesenchymal stem cell-derived extracellular vesicles carrying miR-21-5p in hyperoxia-induced lung injury. Stem Cell Rev Rep 2022; 18 (03) 1007-1024
50 Yang B, Chen Y, Shi J. Reactive oxygen species (ROS)-based nanomedicine. Chem Rev 2019; 119 (08) 4881-4985
51 Arslan F, Lai RC, Smeets MB. et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res 2013; 10 (03) 301-312
52 Lai RC, Yeo RW, Tan KH, Lim SK. Mesenchymal stem cell exosome ameliorates reperfusion injury through proteomic complementation. Regen Med 2013; 8 (02) 197-209
53 Ten VS, Ratner V. Mitochondrial bioenergetics and pulmonary dysfunction: current progress and future directions. Paediatr Respir Rev 2020; 34: 37-45
54 Ratner V, Sosunov SA, Niatsetskaya ZV, Utkina-Sosunova IV, Ten VS. Mechanical ventilation causes pulmonary mitochondrial dysfunction and delayed alveolarization in neonatal mice. Am J Respir Cell Mol Biol 2013; 49 (06) 943-950
55 Ratner V, Starkov A, Matsiukevich D, Polin RA, Ten VS. Mitochondrial dysfunction contributes to alveolar developmental arrest in hyperoxia-exposed mice. Am J Respir Cell Mol Biol 2009; 40 (05) 511-518
56 Yang S, Li F, Lu S. et al. Ginseng root extract attenuates inflammation by inhibiting the MAPK/NF-κB signaling pathway and activating autophagy and p62-Nrf2-Keap1 signaling in vitro and in vivo. J Ethnopharmacol 2022; 283: 114739
57 Xia L, Zhang C, Lv N. et al. AdMSC-derived exosomes alleviate acute lung injury via transferring mitochondrial component to improve homeostasis of alveolar macrophages. Theranostics 2022; 12 (06) 2928-2947
58 Chen C, Jin Y, Jin H. et al. Adipose mesenchymal stem cells-derived exosomes attenuated hyperoxia-induced lung injury in neonatal rats via inhibiting the NF-κB signaling pathway. Pediatr Pulmonol 2024; 59 (10) 2523-2534
59 Lim R, Muljadi R, Koulaeva E. et al. Activin A contributes to the development of hyperoxia-induced lung injury in neonatal mice. Pediatr Res 2015; 77 (06) 749-756
60 Sun Y, Chen C, Liu Y. et al. Adipose stem cells derived exosomes alleviate bronchopulmonary dysplasia and regulate autophagy in neonatal rats. Curr Stem Cell Res Ther 2024; 19 (06) 919-932
61 Zhang L, Zhao S, Yuan LJ. et al. Autophagy regulates hyperoxia-induced intracellular accumulation of surfactant protein C in alveolar type II cells. Mol Cell Biochem 2015; 408 (1-2): 181-189
62 Zhang L, Zhao S, Yuan L, Wu H, Jiang H, Luo G. Hyperoxia-mediated LC3B activation contributes to the impaired transdifferentiation of type II alveolar epithelial cells (AECIIs) to type I cells (AECIs). Clin Exp Pharmacol Physiol 2016; 43 (09) 834-843
63 Yang W, Chen YB, Wang WJ, Huang C. Repair effect of bone morrow mesenchymal stem cell-derived exosomes on neonatal rats model with bronchopulmonary dysplasia induced by hyperoxia. Guangdong Yixue 2023; 44: 962-969
64 Allen J, Panitch H. Bronchopulmonary dysplasia-a historical perspective. Pediatr Pulmonol 2021; 56 (11) 3478-3489
65 Warner BB, Stuart LA, Papes RA, Wispé JR. Functional and pathological effects of prolonged hyperoxia in neonatal mice. Am J Physiol 1998; 275 (01) L110-L117
66 Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 164 (10 Pt 1): 1971-1980
67 Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell 2019; 176 (06) 1248-1264
68 Thébaud B, Ladha F, Michelakis ED. et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation 2005; 112 (16) 2477-2486
69 Braun RK, Chetty C, Balasubramaniam V. et al. Intraperitoneal injection of MSC-derived exosomes prevent experimental bronchopulmonary dysplasia. Biochem Biophys Res Commun 2018; 503 (04) 2653-2658
70 Xi Y, Ju R, Wang Y. Mesenchymal stem cell-derived extracellular vesicles for the treatment of bronchopulmonary dysplasia. Front Pediatr 2022; 10: 852034
71 Porzionato A, Zaramella P, Dedja A. et al. Intratracheal administration of clinical-grade mesenchymal stem cell-derived extracellular vesicles reduces lung injury in a rat model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2019; 316 (01) L6-L19
72 Weismann CG, Asnes JD, Bazzy-Asaad A, Tolomeo C, Ehrenkranz RA, Bizzarro MJ. Pulmonary hypertension in preterm infants: results of a prospective screening program. J Perinatol 2017; 37 (05) 572-577
73 Mourani PM, Sontag MK, Younoszai A. et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med 2015; 191 (01) 87-95
74 Ong MS, Abman S, Austin ED. et al; Pediatric Pulmonary Hypertension Network and National Heart, Lung, and Blood Institute Pediatric Pulmonary Vascular Disease Outcomes Bioinformatics Clinical Coordinating Center Investigators. Racial and ethnic differences in pediatric pulmonary hypertension: an analysis of the pediatric pulmonary hypertension network registry. J Pediatr 2019; 211: 63-71.e6
75 Kalikkot Thekkeveedu R, Guaman MC, Shivanna B. Bronchopulmonary dysplasia: a review of pathogenesis and pathophysiology. Respir Med 2017; 132: 170-177
76 Jacob SV, Coates AL, Lands LC. et al. Long-term pulmonary sequelae of severe bronchopulmonary dysplasia. J Pediatr 1998; 133 (02) 193-200
77 Cheng T, Mao M, Liu Y. et al. The potential therapeutic effect of human umbilical cord mesenchymal stem cell-derived exosomes in bronchopulmonary dysplasia. Life Sci 2024; 357: 123047
78 Guiot J, Cambier M, Boeckx A. et al. Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3p. Thorax 2020; 75 (10) 870-881
79 Xu C, Hou L, Zhao J. et al. Exosomal let-7i-5p from three-dimensional cultured human umbilical cord mesenchymal stem cells inhibits fibroblast activation in silicosis through targeting TGFBR1. Ecotoxicol Environ Saf 2022; 233: 113302
80 Cheng L, Zhang K, Wu S, Cui M, Xu T. Focus on mesenchymal stem cell-derived exosomes: opportunities and challenges in cell-free therapy. Stem Cells Int 2017; 2017: 6305295
81 Lotfy A, AboQuella NM, Wang H. Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther 2023; 14 (01) 66
82 Mendt M, Rezvani K, Shpall E. Mesenchymal stem cell-derived exosomes for clinical use. Bone Marrow Transplant 2019; 54 (Suppl. 02) 789-792